Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy…
28 analysts rate ALNY Buy on consensus.
Consensus price target: $449.32 (+181.02% upside from $159.89)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| PYOTT DAVID E I director | Jun 1, 2026 | Sale | 921 | $274.19K |
| PYOTT DAVID E I director | Jun 1, 2026 | Sale | 1,222 | $366.44K |
| PYOTT DAVID E I director | Jun 1, 2026 | Sale | 17 | $5.15K |
| PYOTT DAVID E I director | Jun 1, 2026 | Sale | 495 | $148.86K |
| PYOTT DAVID E I director | Jun 1, 2026 | Sale | 1,175 | $351.22K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $3.71B | +65.19% | $313.75M |
| 2024 | $2.25B | +22.97% | $-278.16M |
| 2023 | $1.83B | +76.23% | $-440.24M |
Stock data for ALNY: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics